BACKGROUND: Brain tissue oxygen (PbtO(2)) monitoring is used in severe traumatic brain injury (TBI) patients. How brain reduced PbtO(2) should be treated and its response to treatment is not clearly defined. We examined which medical therapies restore normal PbtO(2) in TBI patients. METHODS: Forty-nine (mean age 40 ± 19 years) patients with severe TBI (Glasgow Coma Scale [GCS] ≤ 8) admitted to a University-affiliated, Level I trauma center who had at least one episode of compromised brain oxygen (PbtO(2) <25 mmHg for >10 min), were retrospectively identified from a prospective observational cohort study. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and PbtO(2) were monitored continuously. Episodes of compromised PbtO(2) and brain hypoxia (PbtO(2) <15 mmHg for >10 min) and the medical interventions that improved PbtO(2) were identified. RESULTS: Five hundred and sixty-four episodes of compromised PbtO2 were identified from 260 days of PbtO2 monitoring. Medical management used in a "cause-directed" manner successfully reversed 72% of the episodes of compromised PbtO(2), defined as restoration of a "normal" PbtO(2) (i.e. ≥ 25 mmHg). Ventilator manipulation, CPP augmentation, and sedation were the most frequent interventions. Increasing FiO(2) restored PbtO(2) 80% of the time. CPP augmentation and sedation were effective in 73 and 66% of episodes of compromised brain oxygen, respectively. ICP reduction using mannitol was effective in 73% of treated episodes, though was used only when PbtO(2) was compromised in the setting of elevated ICP. Successful medical treatment of brain hypoxia was associated with decreased mortality. Survivors (n = 38) had a 71% rate of response to treatment and non-survivors (n = 11) had a 44% rate of response (P = 0.01). CONCLUSION: Reduced PbtO(2) may occur in TBI patients despite efforts to maintain CPP. Medical interventions other than those to treat ICP and CPP can improve PbtO(2). This may increase the number of therapies for severe TBI in the ICU.
BACKGROUND: Brain tissue oxygen (PbtO(2)) monitoring is used in severe traumatic brain injury (TBI) patients. How brain reduced PbtO(2) should be treated and its response to treatment is not clearly defined. We examined which medical therapies restore normal PbtO(2) in TBI patients. METHODS: Forty-nine (mean age 40 ± 19 years) patients with severe TBI (Glasgow Coma Scale [GCS] ≤ 8) admitted to a University-affiliated, Level I trauma center who had at least one episode of compromised brain oxygen (PbtO(2) <25 mmHg for >10 min), were retrospectively identified from a prospective observational cohort study. Intracranial pressure (ICP), cerebral perfusion pressure (CPP), and PbtO(2) were monitored continuously. Episodes of compromised PbtO(2) and brain hypoxia (PbtO(2) <15 mmHg for >10 min) and the medical interventions that improved PbtO(2) were identified. RESULTS: Five hundred and sixty-four episodes of compromised PbtO2 were identified from 260 days of PbtO2 monitoring. Medical management used in a "cause-directed" manner successfully reversed 72% of the episodes of compromised PbtO(2), defined as restoration of a "normal" PbtO(2) (i.e. ≥ 25 mmHg). Ventilator manipulation, CPP augmentation, and sedation were the most frequent interventions. Increasing FiO(2) restored PbtO(2) 80% of the time. CPP augmentation and sedation were effective in 73 and 66% of episodes of compromised brain oxygen, respectively. ICP reduction using mannitol was effective in 73% of treated episodes, though was used only when PbtO(2) was compromised in the setting of elevated ICP. Successful medical treatment of brain hypoxia was associated with decreased mortality. Survivors (n = 38) had a 71% rate of response to treatment and non-survivors (n = 11) had a 44% rate of response (P = 0.01). CONCLUSION: Reduced PbtO(2) may occur in TBI patients despite efforts to maintain CPP. Medical interventions other than those to treat ICP and CPP can improve PbtO(2). This may increase the number of therapies for severe TBI in the ICU.
Authors: F Procaccio; N Stocchetti; G Citerio; M Berardino; L Beretta; F Della Corte; D D'Avella; G L Brambilla; R Delfini; F Servadei; G Tomei Journal: J Neurosurg Sci Date: 2000-03 Impact factor: 2.279
Authors: H van Santbrink; W A vd Brink; E W Steyerberg; J A Carmona Suazo; C J J Avezaat; A I R Maas Journal: Acta Neurochir (Wien) Date: 2003-06 Impact factor: 2.216
Authors: M Oddo; J M Levine; S Frangos; E Carrera; E Maloney-Wilensky; J L Pascual; W A Kofke; S A Mayer; P D LeRoux Journal: J Neurol Neurosurg Psychiatry Date: 2009-03-16 Impact factor: 10.154
Authors: Gaylan L Rockswold; Craig A Solid; Eduardo Paredes-Andrade; Sarah B Rockswold; Jon T Jancik; Robert R Quickel Journal: Neurosurgery Date: 2009-12 Impact factor: 4.654
Authors: Eileen Maloney-Wilensky; Vicente Gracias; Arthur Itkin; Katherine Hoffman; Stephanie Bloom; Wei Yang; Susan Christian; Peter D LeRoux Journal: Crit Care Med Date: 2009-06 Impact factor: 7.598
Authors: Ross P Martini; Steven Deem; N David Yanez; Randall M Chesnut; Noel S Weiss; Stephen Daniel; Michael Souter; Miriam M Treggiari Journal: J Neurosurg Date: 2009-10 Impact factor: 5.115
Authors: Jurgens Nortje; Jonathan P Coles; Ivan Timofeev; Tim D Fryer; Franklin I Aigbirhio; Peter Smielewski; Joanne G Outtrim; Doris A Chatfield; John D Pickard; Peter J Hutchinson; Arun K Gupta; David K Menon Journal: Crit Care Med Date: 2008-01 Impact factor: 7.598
Authors: Michael F Stiefel; Gregory G Heuer; Michelle J Smith; Stephanie Bloom; Eileen Maloney-Wilensky; Vincente H Gracias; M Sean Grady; Peter D LeRoux Journal: J Neurosurg Date: 2004-08 Impact factor: 5.115
Authors: Andrew J Johnston; Luzius A Steiner; Jonathan P Coles; Doris A Chatfield; Tim D Fryer; Peter Smielewski; Peter J Hutchinson; Mark T O'Connell; Pippa G Al-Rawi; Franklin I Aigbirihio; John C Clark; John D Pickard; Arun K Gupta; David K Menon Journal: Crit Care Med Date: 2005-01 Impact factor: 7.598
Authors: Andrew J Johnston; Luzius A Steiner; Doris A Chatfield; Jonathan P Coles; Peter J Hutchinson; Pippa G Al-Rawi; David K Menon; Arun K Gupta Journal: Intensive Care Med Date: 2004-03-27 Impact factor: 17.440
Authors: Jennifer Frontera; Wendy Ziai; Kristine O'Phelan; Peter D Leroux; Peter J Kirkpatrick; Michael N Diringer; Jose I Suarez Journal: Neurocrit Care Date: 2015-06 Impact factor: 3.210
Authors: David O Okonkwo; Lori A Shutter; Carol Moore; Nancy R Temkin; Ava M Puccio; Christopher J Madden; Norberto Andaluz; Randall M Chesnut; M Ross Bullock; Gerald A Grant; John McGregor; Michael Weaver; Jack Jallo; Peter D LeRoux; Dick Moberg; Jason Barber; Christos Lazaridis; Ramon R Diaz-Arrastia Journal: Crit Care Med Date: 2017-11 Impact factor: 7.598